Verification Study of Ciclosporin for Atopic Dermatitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2
divided doses daily for 8 weeks to patients with severe adult atopic dermatitis.
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES